Share

Richard Sylvester receives European Urology 2014 Platinum Award for Excellence

Although Richard Sylvester officially retired in May 2012 after nearly 37 years at EORTC Headquarters, most of which were spent as the head of the Statistics Department, his scientific activities still keep him very busy.

Richard still works one day a week at EORTC Headquarters pursuing his main research interest, non-muscle invasive bladder cancer (NMIBC). The EORTC database of bladder cancer studies provides a valuable source of data for his research on prognostic factors and more specifically the prognostic and predictive effect of age.

Dr. Sylvester recently stepped down as the Statistical Editor of European Urology, and in recognition of his work for the journal, both as editor and reviewer and also for his publications in the journal, he recently received the journal’s 2014 Platinum Award for excellence during the 2014 European Association of Urology (EAU) Congress in Stockholm.

Richard still maintains a number of activities with the EAU and is a member of both the EAU NMIBC Guidelines Panel and the EAU Guidelines Office Board. As part of his work for the EAU Guidelines Office, he chairs the Methodology Committee which is reviewing and updating the methodology used for guideline production.

As a joint project between the EORTC and the EAU, Richard has also launched a new systematic review and individual patient data meta-analysis to try to identify which NMIBC patients benefit from a single immediate instillation of chemotherapy after transurethral resection.

His spare time is devoted to his love of photography and his photographic activities both here in Brussels and with the Royal Photographic Society which is based in the United Kingdom. Photography provides a welcome artistic complement to the more scientific aspects which he will still pursue in his day to day life.

Please join us in congratulating Richard.

John Bean, PhD
EORTC, Medical Science Writer

Back to news list

Related News

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)

  • Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023

  • EORTC Quality of Life measures integrated in CDISC

  • EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma

  • Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia

  • New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023